Mabpharm Osake

Mabpharm EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Mabpharm (2181.HK) 14.8.2026 päivämäärällä on 5,44 M CNY. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −117,91 M CNY — muutos −104,61 % (korkeampi).

EBITDA

5,44 MCNY

YoY

−104,61%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Mabpharm on 2026 5,44 M CNY. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Mabpharm oli 2025 −117,91 M CNY. Se laskee −104,61% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Mabpharm Osakeanalyysi

Mitä Mabpharm tekee? Mabpharm Ltd is a biopharmaceutical company based in Suzhou, China. The company was founded in 2009 and specializes in the development and production of monoclonal antibodies. The business model of Mabpharm is to develop, produce, and sell high-quality biological drugs worldwide. The company works closely with customers to understand their needs and provide customized solutions. Mabpharm is divided into different divisions, each specialized in producing specific products. The main ones are oncology, immunology, cardiology, and infectious diseases. Each division offers a portfolio of products tailored to the needs of patients. In the field of oncology, Mabpharm offers a range of monoclonal antibodies that can be used to treat cancer. This includes therapies for breast cancer, gastric cancer, colorectal cancer, and lung cancer. The products have all been developed in collaboration with renowned partners worldwide and undergo rigorous clinical testing before being brought to market. Mabpharm's immunology division focuses on developing drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The products in this division have been specifically designed to regulate the immune system and suppress inflammation symptoms. The cardiology division of Mabpharm is dedicated to the development of drugs for the prevention and treatment of cardiovascular diseases. The products include antibodies for the treatment of lipid metabolism disorders and blood clots. Mabpharm's cardiovascular products also include a cholesterol-lowering medication that helps prevent heart attacks and strokes. In the infectious diseases division, Mabpharm has developed products for the treatment of hepatitis B and hepatitis C. These can reduce viral load and improve liver function. Furthermore, Mabpharm is also involved in the development of vaccines against COVID-19. Mabpharm has become a leading provider of monoclonal antibodies and biological drugs in China and internationally. The company works closely with academics and researchers to find innovative solutions and stay up to date with the latest scientific advancements. In conclusion, Mabpharm is an innovative company specializing in the research and development of biological drugs of all kinds. The company has a wide range of products that have been developed to meet the needs of patients worldwide. Mabpharm has emerged as a key player in the global market for biological drugs in recent years and is a company to watch when it comes to the future of biotechnology. Mabpharm on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Mabpharm osakkeesta

Yhtiön Mabpharm EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 5,44 M CNY vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Mabpharm muuttui arvosta −117,91 M CNY arvoon 5,44 M CNY, mikä edustaa −104,61 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Mabpharm:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n CNY on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Mabpharm historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Mabpharm

Kaikki tunnusluvut — Mabpharm